Print Page | Sign In | Join Today
News & Press: Company News

NIH awards Synthonics for Development of Metal Coordinated Levodopa

Wednesday, November 20, 2013  
Share |
Synthonics, Inc., a specialty pharmaceutical company focused on the discovery and development of metal coordinated pharmaceuticals, has had its Progress Report and Budget approved in the amount of $816,958 for the second installment of a Phase II grant originally approved in July of 2012 by the National Health Institute’s (NIH).

"The approval of the Progress Report and Budget demonstrates Synthonics' ability to meet timelines, advance the development of MCP-311 (metal coordinated levodopa) and control costs in the first year of the grant" says Kenneth Slepicka, Chief Executive Officer at Synthonics.

Synthonics' goal is to develop an orally administered product that will help patients worldwide who suffer from Parkinson's disease better manage their symptoms. Although Parkinson's disease cannot be cured, it can often be managed using levodopa, which appears to be uniquely capable of facilitating motor control among Parkinson's disease patients. It has proven very difficult, however, to optimize the delivery of orally administered levodopa with currently available products. Patients are often required to take doses several times a day. Even with such frequent dosing, advanced Parkinson's patients frequently have too much or too little of the drug in their bloodstream, resulting in abnormal and involuntary muscle movements.

Our Sponsors

Sign up for our newsletter
800 E. Leigh St.  |  Richmond, Va 23219-1534  |  PH: 804.643.6360  |  Email Us
Stay Connected